Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PharmaCyte Biotech, Inc.PMCB · Entity 8256 | Director | March 31, 2026 | July 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PharmaCyte Biotech, Inc.
Report date March 31, 2026 · Filed July 17, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-31 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-03-31 · Other · Acquired 0 · Balance 0 F1: The reported grant was made in error and has been cancelled. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported grant was made in error and has been cancelled.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2026 Filed Apr 2, 2026 22:16 UTC | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | GrantStock Option (Right to Buy) · Derivative | 119,170 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001683168-26-002630 · ownership.xml · derivative · entry 1 Abecassis Michael M · CIK 0001879281 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,170 Underlying: Common Stock · 119,170 shares Expires 2036-03-30 F1 · derivative.exercise_date: The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Abecassis. Read SEC document |
| March 31, 2026 Filed Jul 17, 2026 21:00 UTC Amendment | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | OtherStock Option (Right to Buy) · Derivative | 0 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-26-005621 · ownership.xml · derivative · entry 1 Abecassis Michael M · CIK 0001879281 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · Not disclosed shares Expires not disclosed F1 · security: The reported grant was made in error and has been cancelled. F1 · derivative.exercise_price: The reported grant was made in error and has been cancelled. F1 · date: The reported grant was made in error and has been cancelled. F1 · kind: The reported grant was made in error and has been cancelled. F1 · shares: The reported grant was made in error and has been cancelled. F1 · price: The reported grant was made in error and has been cancelled. F1 · derivative.exercise_date: The reported grant was made in error and has been cancelled. F1 · derivative.expiration_date: The reported grant was made in error and has been cancelled. F1 · derivative.underlying: The reported grant was made in error and has been cancelled. F1 · derivative.underlying_shares: The reported grant was made in error and has been cancelled. F1 · balance_after: The reported grant was made in error and has been cancelled. Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 22:06 UTC | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | Tax withholdingCommon Stock | 16,875 | $1.02 | $17,212.50 |
DisclosureSEC source: 0001683168-25-009112 · ownership.xml · nonDerivative · entry 2 Abecassis Michael M · CIK 0001879281 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,292 F1 · shares: Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction. Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 22:06 UTC | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-25-009112 · ownership.xml · nonDerivative · entry 1 Abecassis Michael M · CIK 0001879281 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,167 Read SEC document |
| April 25, 2025 Filed Dec 12, 2025 22:06 UTC | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | GrantStock Option (Right to Buy) · Derivative | 63,233 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001683168-25-009112 · ownership.xml · derivative · entry 4 Abecassis Michael M · CIK 0001879281 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,233 Underlying: Common Stock · 63,233 shares Expires 2035-04-24 F2 · derivative.exercise_date: The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Abecassis. This transaction is late due to an inadvertent administrative error and not any error of Mr. Abecassis. Read SEC document |
| April 30, 2024 Filed Jul 17, 2024 20:58 UTC | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | GrantStock Option (Right to Buy) · Derivative | 38,009 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001683168-24-004915 · ownership.xml · derivative · entry 1 Abecassis Michael M · CIK 0001879281 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,009 Underlying: Common Stock · 38,009 shares Expires 2034-04-30 F1 · derivative.exercise_date: The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Abecassis. This transaction is late due to an inadvertent administrative error and not any error of Mr. Abecassis. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 22:00 UTC | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | GrantStock Option (Right to Buy) · Derivative | 61,248 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001683168-23-008429 · ownership.xml · derivative · entry 1 Abecassis Michael M · CIK 0001879281 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,248 Underlying: Common Stock · 61,248 shares Expires 2033-11-20 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.